Herbals and natural dietary supplements in psychiatric practice

Recent Patents on CNS Drug Discovery

Volumn 5, Issue 2, 2010, Pages 164-171

  Chiappedi, Matteo ^a,b,c   Bejor, Maurizio ^a,b  

^a IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^b Francesco Bonaccorsi Foundation   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

B vitamins; Folate; Ginkgo; Herbs; Inositol; Kava; Natural medicine; Nutritional supplements; Omega 3 fatty acids; SAMe; St. John's wort; Valerian

Indexed keywords

ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CYANOCOBALAMIN; ESTROGEN; FLUOXETINE; FOLIC ACID; GINKGO BILOBA EXTRACT; HYPERICUM PERFORATUM EXTRACT; ICOSAPENTAENOIC ACID; INOSITOL; KAVA EXTRACT; LAMOTRIGINE; MOOD STABILIZER; OMEGA 3 FATTY ACID; PENTOBARBITAL; PROTEINASE INHIBITOR; PYRIDOXINE; RISPERIDONE; S ADENOSYLMETHIONINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THIOPENTAL; VALERIAN;

ALZHEIMER DISEASE; ANXIETY; ANXIETY DISORDER; ARTICLE; ATAXIA; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BLOOD CLOTTING TIME; CLINICAL TRIAL; COORDINATION DISORDER; CYANOCOBALAMIN DEFICIENCY; DEPRESSION; DIET SUPPLEMENTATION; DIZZINESS; DROWSINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG OVERDOSE; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL SYMPTOM; HAIR DISCOLORATION; HALITOSIS; HERBAL MEDICINE; HUMAN; HYPOMANIA; INSOMNIA; KAVAISM; MAJOR DEPRESSION; MANIA; MEMORY DISORDER; MENTAL DISEASE; NAUSEA; OPTIMAL DRUG DOSE; OXIDATION; PANIC; PELLAGRA; PHOTODERMATOSIS; PRIORITY JOURNAL; SCHIZOPHRENIA; SEDATION; SEIZURE; SHELF LIFE; SIDE EFFECT; SKIN MANIFESTATION;

ANXIETY DISORDERS; DIETARY SUPPLEMENTS; HUMANS; MOOD DISORDERS; PLANT PREPARATIONS; QUALITY CONTROL; SCHIZOPHRENIA;

EID: 77953849156     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488910791213158     Document Type: Article

References (107)

1. Demyttenaere K, Bruffaerts R, Posada-Villa J, Gasquet I, Kovess V, Lepine JP, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA 2004; 291(21): 2581-90.
2. Murray CJL, Lopez AD. The global burden of disease: Acomprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Harvard Press Edition: UK 1996.
3. Young SN. Clinical nutrition: 3. The fuzzy boundary between nutrition and psycopharmacology. CMAJ 2002; 166(2): 205-9.
4. Wu P, Fuller C, Liu X, Lee H-C, Fan B, Hoven CW, et al. Use of complementary and alternative medicine in women with depression: results of a national survey. Psychiatr Serv 2007; 58(3): 349-56.
5. Burg MA, Hatch RL, Neims AH. Lifetime use of alternative therapy: A study of Florida residents. South Med J 1998; 91(12): 1126-13.
6. Schatzberg AF, Cole JO, DeBattista C. Herbals and dietary supplements. In: Schatzberg AF, Cole JO, DeBattista C, Eds. Manual of Clinical Psychopharmacology. American Psychiatric Publishing: USA 2007; 619-39.
7. Bennett DA, Phun L, Polk JF, Voglino SA, Zlotnik V, Raffa RB. Neuropharmacology of St. John's wort (Hypericum). Ann Pharmacother 1998; 32(11): 1201-8.
8. Thiele B, Ploch M, Brink I. Modulation of cytokine expression by Hypericum extract. Nevenheilkunde 1993; 12: 353-6.
9. Wagner H, Bladt S. Pharmaceutical quality of hypericum extract. Nevenheilkunde 1993; 12: 357-8.
10. Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St. John's Wort) in major depression: A randomized controlled trial. JAMA 2002; 287(14): 1807-14.
11. Fava M, Alpert J, Nierenberg AA, Mischoulon D, Otto MW, Zajecka J, et al. A double-blind, randomized trial of St. John's Wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol 2005; 25(5): 441-7.
12. Kasper S, Anghelescu IG, Szegedi A, Dienel A, Kieser M. Superior efficacy of St. John's Wort extract WS 5570 compared to placebo in patients with major depression: A randomized, double-blind, placebo-controlled, multi-center trial. BMC Med 2006; 4: 14
13. Anghelescu IG, Kohnen R, Szegedi A, Klement S, Kieser M. Comparison of Hypericum extract WS 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: Results from a randomized multicenter study. Pharmacopsychiatry 2006; 39(6): 213-9.
14. Linde K, Mulrow CD, Berner M, Egger M. St. John's wort for depression. Cochrane Database Syst Rev 2005; 18(2): CD000448.
15. Woelk H, Burkhard G, Grunwald J. Evaluation of the benefits and risks of Hypericum extract LI 160 based on a drug monitoring study with 3250 patients. Nervenheilkunde 1993; 12: 308-13
16. Stevinson C, Ernst E. Can St. John's wort trigger psychoses? Int J Clin Pharmacol Ther 2004; 42(9): 473-80.
17. Hu Z, Yang X, Ho PC, Chan SY, Heng PW, Chan E, et al. Herb-drug interactions: A literature review. Drugs 2005; 65(9): 1239-82.
18. Markowitz JS, Donovan JL, DeVane CL, Taylor RM, Wang J-S, Ruan Y, et al. Effect of St. John's wort on drug metabolism by induction of cytochrome p450 3A4 enzyme. J Am Med Assoc 2003; 290(11): 1500-504.
19. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St. John's wort. Lancet 2000; 335: 547-8.
20. Whitten DL, Myers SP, Hawrelak JA, Wohlmuth H. The effect of St John's wort extracts on CYP3A: A systematic review of prospective clinical trials. Br J Clin Pharmacol 2006; 62(5): 512-26.
21. Stoll AL, Locke CA. Omega-3 fatty acids in mood disorders: A review of neurobiological and clinical actions. In: Mischoulon D, Rosenbaum J, Eds. Natural medications in psychiatric disorders. Lippincott Williams & Wilkins: Australia 2002; 13-34.
22. Adams PB, Lawson S, Sanigorski A, Sinclair AJ. Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids 1996; (31SUPPL): S157-S61.
23. Edwards R, Peet M, Shay J, Horrobin D. Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J Affect Disord 1998; 48(2-3): 149-55.
24. Kidd PM. Bipolar disorder and cell membrane dysfunction. Progress toward integrative management. Altern Med Rev 2004; 9(2): 107-35.
25. Fenton WS, Hibbeln J, Knable M. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biol Psychiatry 2000; 71(1 SUPPL): 228S-231S.
26. Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 2002; 59(10): 913-9.
27. Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, et al. Omega-3 fatty acids in bipolar disorder: A preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999; 56(5): 407-12.
28. Keck PE, Mintz J, McElroy SL, Freeman M, Suppes T, Frye M, et al. Double-blind, randomized, placebo-controlled trial of ethyl-eicosapetanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry 2006; 60(9): 1020-22.
29. Frangou S, Lewis M, McCrone P. Efficacy of ethyl-eicosa-pentaenoic acid in bipolar depression: Randomized double-blind placebo-controlled study. Br J Psychiatry 2006; 188: 46-50.
30. Montgomery P, Richardson AJ. Omega-3 fatty acids for bipolar disorder. Cochrane Database Syst Rev 2008; (2): CD005169.
31. Kraguljac NV, Montori VM, Pavuluri M, Chai HS, Wilson BS, Unal SS. Efficacy of omega-3 Fatty acids in mood disorders-a systematic review and metaanalysis. Psychopharmacol Bull 2009; 42(3): 39-54.
32. Mischoulon D. Update and critique of natural remedies as antidepressant treatments. Psychiatr Clin N Am 2007; 30(1): 51-68.
33. Kjeldsen-Kragh J, Lund JA, Riise T, Finnanger B, Haaland K, Finstad R, et al. Diatary omega-3 fatty acid supplementation with n-3 fatty acids and naproxen treatment in patients with rheumatoid arthritis. J Rheumatol 1992; 19(10): 1531-6.
34. Parker G, Parker K. Which antidepressants flick the switch? Aust NZ J Psychiatry 2003; 57: 715-6.
35. Cagampang, G., Elander, L., Bello, A. Storage stable creme filling fortified with omega-3 fatty acids. US20080171128 (2008).
36. Freeman MP, Hibbeln JR, Wisner KL, Davis JM, Mischoulon D, Peet M, et al. Omega-3 fatty acids: Evidence basis for treatment and future research in psychiatry. J Clin Psychiatr 2006; 67(12): 1954-67.
37. Fava M, Borus JS, Alpert JE, Nierenberg AA, Rosenbaum JF, Bottiglieri T. Folate, vitamin B12, and homocysteine in major depressive disorder. Am J Psychiatry 1997; 154(3): 426-8.
38. Papakostas GI, Petersen T, Lebowitz BD, Mischoulon D, Ryan JL, Nierenberg AA, et al. The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine. Int J Neuropsychopharmacol 1999; 51: 527-34
39. Abouh-Saleh MT, Coppen A. Folic acid and the treatment of depression. J Psychosom Res 2006; 61(3): 285-7.
40. Alpert JE, Mischoulon D, Rubenstein GE, Bottonari K, Nierenberg AA, Fava M. Folinic acid (leucovorin) as an adjunctive treatment for SSRI-refractory depression. Ann Clin Psychiatry 2002; 14(1): 33-8.
41. Shane B. Folate and vitamin B12 metabolism: Overview and interaction with riboflavin, vitamin B6, and polymorphisms. Food Nutr Bull 2008; 29(2 SUPPL): S5-S16.
42. Hintikka J, Tolmunen T, Tanskanen A, Viinamäki H. High vitamin B12 level and good treatment outcome may be associatedin major depressive disorder. BMC Psychiatry 2003; 3: 17
43. Shorvon SD, Carney MW, Chanarin I, Reynolds EH. The neuropsychiatry of megaloblastic anaemia. Br Med J 1980; 281(6247): 1036-8.
44. Coppen A, Bolander-Gouaille C. Treatment of depression: Time to consider folic acid and vitamin B12. J Psychopharmacol 2005; 19(1): 59-65.
45. Commission of the European Communities. Nutrient and energy intakes for the European Community. Reports of the Scientific Committee for Food, Thirty-first series, Office for Official Publications of the European Communities, Luxembourg 1993
46. Merete C, Falcon LM, Tucker KL. Vitamin B6 is associated with depressive symptomatology in Massachusetts elders. J Am Coll Nutr 2008; 27 (3): 421-7.
47. Williams AL, Cotter A, Sabina A, Girard C, Goodman J, Katz DL. The role for vitamin B-6 as treatment for depression: a systematic review. Fam Pract 2005; 22 (5): 532-7.
48. Berlanga C, Ortega-Soto H, Ontiveros M, Senties H. Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipramine. Psychiatry Res 1992; 44: 257-62.
49. Bressa GM. S-Adenosyl-L-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol Scand suppl 1994; 154: 7-14.
50. Williams AL, Girard C, Jui D, Sabina A, Katz DL. S-Adenosylmethionine (SAMe) as treatment for depression: A systematic review. Clin Invest Med 2005; 28(3): 132-9.
51. Bottiglieri T, Hyland K, Reynolds EH. The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders. Drugs 1994; 48(2): 137-52.
52. Najm WI, Reinsch S, Hoehler F, Tobis JS, Harvey PW. S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: A double-blind cross-over trial. [ISRCTN36233495]. BMC Musculoskelet Disord 2004; 5: 6.
53. Fava M, Giannelli A, Rapisarda V, Patralia A, Guaraldi GP. Rapidity of onset of the antidepressant effect of parenteral S-adenosyl-L-methionine. Psychiatry Res 1995; 56(3): 295-7.
54. Mischoulon D, Fava M. Role of S-adenosyl-L-methionine in the treatment of depression: A review of the evidence. Am J Clin Nutr 2002; 76(5): 1158S-61S.
55. Carney MW, Chary TK, Bottiglieri T, Reynolds EH. The switch mechanism and the bipolar/unipolar dichotomy. Br J Psychiatry 1989; 154: 48-51
56. Kofman O, Bersudsky Y, Vinnitsky I, Alpert C, Belmrker RH. The effect of peripheral inositol injection on rat motor activity models of depression. Int J Med Sci 1999; 29: 580-6
57. Einat H, Karbovski H, Korik J, Tsalah D, Belmaker RH. Inositol reduces depressive-like behaviors in two different animal models of depression. Psychopharmacol 1999; 144(2): 158-62.
58. Levine J, Barak Y, Gonzalves M, Szor H, Elizur A, Kofman O, et al. Double-blind, controlled trial of inositol treatment of depression. Am J Psychiatry 1995; 152 (5): 792-4.
59. Levine J, Mishori A, Susnosky M, Martin M, Belmaker RH. Combination of inositol and serotonin reuptake inhibitors in the treatment of depression. Biol Psychiatry 1999; 45(3): 270-3.
60. Nierenber AA, Ostacher MJ, Calabrese JR, Ketter TA, Marangell LB, Miklowitz DJ, et al. Treatment-resistant bipolar depression: A STEP-BD equipoise randomized effectiveness trial of antidepres-sant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry 2006; 163(2): 210-6.
61. Taylor MJ, Wilder H, Bhagwagar Z, Geddes J. Inositol for depressive disorders. Cochrane Database Syst Rev 2004; (2): CD004049.
62. Saeed SA, Bloch RM, Antonacci DJ. Herbal and dietary supplements for treatment of anxiety disorders. Am Fam Physician 2007; 76(4): 549-56.
63. Kinrys G, Coleman E, Rothstein E. Natural remedies for anxiety disorders: Potential use and clinical applications. Depress Anxiety 2009; 26(3): 259-65.
64. Sarris J. Herbal medicines in the treatment of psychiatric disorders: A systematic review. Phytother Res 2007; 21(8): 703-716.
65. Woelk H, Arnoldt KH, Kieser M, Hoerr R. Ginkgo biloba special extract EGb 761® in generalized anxiety disorder and adjustment disorder with anxious mood: A randomized, double-blind, placebo-controlled trial. J Psychiatr Res 41(6): 472-80.
66. Hunt C, Slade T, Andrews G. Generalized anxiety disorder and major depressive disorder comorbidity in the National Survey of Mental Health and Well-Being. Depress Anxiety 2004; 20(1): 23-31.
67. Rex A, Morgenste8rn E, Fink H. Anxiolytic-like effects of kava-kava in the elevated plus maze test-a comparison with diazepam. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26(5): 855-60.
68. Cairney S, Maruff P, Clough AR. The neurobehavioural effects of kava. Aust N Z J Psychiatry 2002; 36(5): 657-62.
69. Singh YN. Kava: An overview. J Ethnopharmacol 1992; 37(1): 13-45.
70. Seitz U, Schule A, Gleitz J. 3H-monoamine uptake inhibition properties of kava pyrones. Planta Med 1997; 63(6): 548-9.
71. Baum SS, Hill R, Rommelspacher H. Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats. Prog Neuropsychopharmacol Biol Psychiatry 1998; 22(7): 1105-20.
72. Sarris J, Kavanagh DJ, Byrne G, Bone KM, Adams J, Deed G. The Kava Anxiety Depression Spectrum Study (KADSS): A randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum. Psychopharmacology (Berl) 2009; 05(3): 399-407.
73. Teschke R, Genthner A, Wolff A. Kava hepatotoxicity: Comparison of aqueous, ethanolic, acetonic kava extracts and kava-herbs mixtures. J Ethnopharmacol 2009; 123(3): 378-84.
74. Spillane PK, Fisher DA, Currie BJ. Neurological manifestations of kava intoxication. Med J Aust 1997; 167(10): 172-3.
75. Norton SA, Ruze P. Kava dermopathy. J Am Acad Dermatol 1994; 31(1): 89-97.
76. DeSmet PA. Health risks of herbal remedies; An update. Clin Pharmacol Ther 2004; 76(1): 1-17.
77. Ang-Lee MK, Moss J, Juan CS. Herbal medicines and perioperative care. JAMA 2001; 286(20): 208-16.
78. Bent S, Padula A, Moore D, Patterson M, Mehling W. Valerian for sleep: A systematic review and meta-analysis. Am J Med 2006; 119(12): 1005-12.
79. Taibi DM, Landis CA, Petry H, Vitiello MV. A systematic review of valerian as a sleep aid: Safe but not effective. Sleep Med Rev 2007; 11(3): 209-30.
80. Ortiz JG, Nieves-Natal J, Chavez P. Effects of Valeriana officinalis extracts on [3H]flunitrazepam binding, synaptosomal [3H]GABA uptake, and hippocampal [3H]GABA release. Neurochem Res 1999; 24(11): 1373-8.
81. Benke D, Barberis A, Kopp S, Altmann KH, Schubiger M, Vogt KE, et al. GABA A receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extracts. Neuropharmacology 2009; 56(1): 174-81.
82. Donath F, Quispe S, Diefenbach K, Maurer A, Fietze I, Roots I. Critical evaluation of the effect of valerian extract on sleep srtucture and sleep quality. Pharmacopsychiatry 2000; 33(2): 47-53.
83. Abebe W. Herbal medication: Potential for adverse interactions with analgesic drugs. J Clin Pharm Ther 2002; 27: 391-401.
84. Corte DCL, Fachinetto R, Colle D, Pereira RP, Avila DS, Villarinho JG, et al. Potentially adverse interactions between haloperidol and valerian. Food Chem Toxicol 2008; 46(7): 2369-75.
85. Hellum BH, Hu Z, Nilsen OG. The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Basic Clin Pharmacol Toxicol 2007; 100(1): 23-30.
86. European Medicines Agency (EMEA). Evaluation of Medicines for Human Use. Community herbal Monograph on Valerian root (Valeriana radix). Doc. Ref. EMEA/HMPC/340719/2005, 2005; 1-5.
87. Valencia, G., DeLaRosa, D.M. Formulations containing borojo. US20090246231A1 (2009)
88. Peet M. Eicosapentaenoic acid in the treatment of schizophrenia and depression: Rationale and preliminary double-blind clinical trial results. Prostaglandins Leukot Essent Fatty Acids 2003; 69(6): 477-85.
89. Ermsley R, Myburgh C, Oosthuizen P, van Rensburg SJ. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry 2002; 159(9): 1596-8.
90. Birks J, Evans GJ. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2009; 1: CD003120.
91. Taylor MJ. Strategies for managing antidepressant-induced sexual dysfunction: A review. Curr Psychiatry Rep 2006; 8(6): 431-6.
92. Mahadevan S, Park Y. Multifaceted therapeutic benefits of Ginkgo biloba L.: Chemistry, efficacy, safety, and uses. J Food Sci 2008; 73 (1): R1 4-9.
93. Chan PC, Xia Q, Fu PP. Ginkgo biloba leave extract: biological, medicinal, and toxicological effects. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2007; 25(3): 211-44.
94. Bent S, Goldberg H, Padula A, Avins AL. Spontaneous bleeding associated with ginkgo biloba: A case report and systematic review of the literature. J Gen Intern Med 2005; 20(7): 657-61.
95. Zink T, Chaffin J. Herbal health products: What family physicians need to know. Am Fam Physycian 1998; 58(5): 1133-40.
96. Sloley BD, Urichuk LJ, Morley P, Durkin J, Shan JJ, Pang PK, et al. Identification of kaempferol as a monoamine oxidase inhibitor and potential neuroprotectant in extracts of Ginkgo biloba leaves. J Pharm Pharmacol 2000; 52(4): 451-9.
97. Miller LG. Herbal medicinals. Selected considerations focusing on known or potential drug-herb interactions. Arch Intern Med 1998; 158(20): 2200-11.
98. Crone CC, Gabriel G. Herbal and nonherbal supplements in medical-psychiatric patient populations. Psychiatr Clin North Am 2002; 25(1): 211-30.
99. Lipp FJ. The efficacy, history, and politics of medicinal plants Altern Ther Health Med 1996; 2(4): 36-41.
100. Werneke U. Risk management of nutritional supplements in chronic illness: The implications for the care of cancer and depression. Proc Nutr Soc 2007; 66(4): 483-92.
101. Minatelli JA, Hills S, Moerck RE, Nguyen U. New plant derived seed extract rich in essentially fatty acids derived from Salvia hispanica l. seed: Composition of matter, manufacturing process and use. US20090258081A1 (2009).
102. Markowitz JS, von Moltke LL, Donovan JL. Predicting interactions between conventional medications and botanical products on the basis of in vitro investigations. Mol Nutr Food Res 2008; 52(7): 747-54.
103. Eisenberg DM, Davis RB, Ettner SL, Wilkey S, Kessler RC, Appel S, et al. Trends in alternative medicine use in the United States, 1990-1997. JAMA 1998; 280(18): 1569-75.
104. Laugero, K.D., Hanley, M.R., Mack, C.M., Parkes, D.G., Young, A.A. Amylin and amylin agonists for treating psychiatric diseases and disorders. US20080287355 (2008)
105. Roth JD, Maier H, Chen S, Roland BL. Implications of amylin receptor agonism: Integrated neurohormonal mechanisms and therapeutic applications. Arch Neurol 2009; 66(3): 306-10.
106. Brucker, D., Sweeney, M., Breen, T. Functionalized coffee. US20080057162A1 (2008)
107. World Health Organization. International Classification of Functioning, Disability and Health. Geneva: Switzerland 2001.